Pharvaris
PHVS
36 hedge funds and large institutions have $1.14B invested in Pharvaris in 2023 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 13 increasing their positions, 3 reducing their positions, and 3 closing their positions.
500% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 3
333% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 3
89% more capital invested
Capital invested by funds: $607M → $1.14B (+$537M)
71% more funds holding
Funds holding: 21 → 36 (+15)
28.64% more ownership
Funds ownership: 71.14% → 99.78% (+29%)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$40.2M |
| 2 |
VA
VR Adviser
New York
|
+$37.1M |
| 3 |
GA
General Atlantic
New York
|
+$35.4M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$18.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$17.8M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.56M |
| 3 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$692K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$366K |
| 5 |
Walleye Capital
New York
|
-$63.7K |
PHVS Hedge Fund Activity: Q4 2023 in Review
36 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Pharvaris (PHVS) for Q4 2023, worth a combined $1.14B — up 89% from $607M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new PHVS positions and 3 closed out — a net gain of 15 holders — while 13 added to existing stakes and 3 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $40.2M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $17.8M.
- 36 institutional investors held Pharvaris (PHVS) as of Q4 2023, up from 21 in Q3 2023.
- Funds reported $1.14B of Pharvaris stock for Q4 2023, up 89% quarter-over-quarter.
- 18 funds opened new Pharvaris positions in Q4 2023 and 3 closed out, a net change of +15 holders.
- The largest Pharvaris buyer in Q4 2023 was Fidelity Investments, an estimated $40.2M added.
- The largest Pharvaris seller in Q4 2023 was Bain Capital Life Sciences Investors, an estimated $17.8M sold.
Based on aggregated 13F filings for Q4 2023.